Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Runshi Pharmaceutical has an active pipeline with at least five clinical-stage programs targeting oncology indications. Its most advanced assets are in Phase 3 trials for small cell lung cancer and metastatic esophageal squamous cell carcinoma. The company develops both small molecules and biologics including monoclonal antibodies and antibody-drug conjugates. It is a subsidiary/joint venture under CSPC Pharmaceutical Group.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shanghai Runshi Pharmaceutical.